


Ask a doctor about a prescription for RISPERDAL CONSTA 50 mg POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INTRAMUSCULAR INJECTION
Package Leaflet: Information for the User
risperidone
Read all of this leaflet carefully before you start using this medicine, because it contains important information for you., as it contains important information for you.
Risperdal Consta belongs to a group of medicines called “antipsychotics”.
Risperdal Consta is used in the maintenance treatment of schizophrenia, which is characterized by seeing, hearing, or feeling things that are not there, believing in something that is not true, or unusually feeling suspicious or confused.
Risperdal Consta is intended for patients who are currently being treated with oral antipsychotics (e.g., tablets, capsules).
Risperdal Consta may help reduce the symptoms of your illness and prevent them from coming back.
Do not use Risperdal Consta
Warnings and precautions
Talk to your doctor or pharmacist before using Risperdal Consta if:
If you are unsure about any of the above, talk to your doctor or pharmacist before using Risperdal or Risperdal Consta.
Because it has been very rarely observed in patients treated with Risperdal Consta that there is a dangerously low number of a type of white blood cell necessary to fight infections in the blood, your doctor may check your white blood cell count.
Rarely, allergic reactions occur after receiving Risperdal Consta injections, even if you have previously tolerated oral risperidone. Seek medical attention immediately if you experience hives, swelling of the throat, itching, or breathing problems, as these may be symptoms of a severe allergic reaction.
Risperdal Consta may cause you to gain weight. Significant weight gain can affect your health unfavorably. Your doctor will regularly monitor your weight.
Because diabetes mellitus or worsening of pre-existing diabetes mellitus has been seen in patients taking Risperdal, your doctor should check for signs of elevated blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be monitored regularly.
Risperdal Consta often increases the levels of a hormone called “prolactin”. This can cause side effects such as menstrual disorders or fertility problems in women or breast swelling in men (see Possible side effects). If these side effects occur, it is recommended to evaluate prolactin levels in the blood.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are considering eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Elderly patients with dementia
Risperdal Consta is not used in elderly patients with dementia.
If you or your caregiver notice a sudden change in your mental state or the sudden appearance of weakness or numbness in the face, arms, or legs, especially on one side, or confused speech, even if only for a short time, seek medical attention immediately. It may be a sign of a stroke.
Patients with kidney or liver problems
Although oral risperidone has been studied, Risperdal Consta has not been studied in patients with kidney or liver problems. Risperdal Consta should be administered with caution in this group of patients.
Using Risperdal Consta with other medicines
Tell your doctor or pharmacist if you are using or have recently used or may need to use any other medicines.
It is especially important that you talk to your doctor or pharmacist if you are taking any of the following
The following medicines may reduce the effect of risperidone
If you start or stop taking these medicines, you may need a different dose of risperidone.
The following medicines may increase the effect of risperidone
If you start or stop taking these medicines, you may need a different dose of risperidone.
If you are unsure about any of the above, talk to your doctor or pharmacist before using Risperdal Consta.
Using Risperdal Consta with food, drinks, and alcohol
You should avoid consuming alcohol while using Risperdal Consta.
Pregnancy, breastfeeding, and fertility
Driving and using machines
Dizziness, fatigue, and vision problems have been observed during treatment with Risperdal Consta. Do not drive or use tools or machinery without consulting your doctor first.
Risperdal Constacontains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per dose; it is essentially “sodium-free”.
Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Risperdal Consta is administered by intramuscular injection into the arm or buttock every two weeks, by a healthcare professional. Injections should be alternated between the left and right sides and should not be administered intravenously.
The recommended dose is as follows:
Adults
Initial dose
If your daily dose of oral risperidone (e.g., tablets) was 4 milligrams or less during the two weeks prior, your starting dose should be 25 milligrams of Risperdal Consta.
If your daily dose of oral risperidone (e.g., tablets) was more than 4 milligrams during the two weeks prior, you may be given a dose of 37.5 milligrams of Risperdal Consta as the starting dose.
If you are currently being treated with another oral antipsychotic that is not risperidone, your starting dose of Risperdal Consta will depend on your current treatment. Your doctor will choose Risperdal Consta 25 mg or 37.5 mg.
Your doctor will decide if this dose of Risperdal Consta is suitable for you.
Maintenance dose
If you use more Risperdal Consta than you should
It is recommended to take the packaging and the package leaflet of the medicine to the healthcare professional.
If you stop using Risperdal Consta
The effects of this medicine will be lost. You should not stop using this medicine unless your doctor tells you to, as you may experience the symptoms again. Make sure to receive your injections every two weeks. If you cannot attend your appointments, contact your doctor immediately to schedule another appointment when you can.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Use in children and adolescents
Children and adolescents under 18 years of age should not receive Risperdal Consta.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctor if you experience any of the following rare adverse effects (may affect up to 1 in 100 patients):
Report immediately to your doctor if you experience any of the following rare adverse effects (may affect up to 1 in 1,000 patients):
The following adverse effects may also occur:
Very Common Adverse Effects (may affect more than 1 in 10 people)
Common Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Frequency Not Known: cannot be estimated from the available data
The following adverse effect has occurred with the use of another medicine called paliperidone, which is very similar to risperidone, so it is also expected to occur with Risperdal Consta: Fast heart rate when standing up.
Reporting of Adverse Effects
If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging. The expiration date is the last day of the month indicated.
Store in a refrigerator (between 2°C and 8°C). If refrigeration is not available, the packaging can be stored below 25°C for a maximum of 7 days before administration. Administer within 6 hours after reconstitution (if stored at 25°C or below).
Store in the original packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Risperdal Consta Composition
The active ingredient is risperidone.
Each Risperdal Consta powder and solvent for prolonged-release suspension for injection contains 50 milligrams of risperidone.
The other components are:
Powder
poly-(d,l-lactide-co-glycolide).
Solvent (solution):
Polysorbate 20, Sodium Carmellose, Disodium Hydrogen Phosphate Dihydrate, Anhydrous Citric Acid, Sodium Chloride, Sodium Hydroxide, Water for Injection.
Appearance of Risperdal Consta and Container Content
Risperdal Consta is available in packs containing 1 to 5 grouped containers.
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Janssen-Cilag, S.A.
Paseo del Club Deportivo 1, Edificio 16
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Janssen Pharmaceutica, N.V
Turnhoutseweg, 30
B-2340, Beerse
Belgium
This medicinal product has been authorized in the EEA Member States with the following names:
Austria: RISPERDAL CONSTA
Belgium: RISPERDAL CONSTA
Cyprus: RISPERDAL CONSTA
Czech Republic: RISPERDAL CONSTA
Denmark: RISPERDAL CONSTA
Estonia: RISPOLEPT CONSTA
Finland: RISPERDAL CONSTA
France: RISPERDAL CONSTA LP
Germany: RISPERDAL CONSTA 25mg, 37.5mg, 50mg
Greece: RISPERDAL CONSTA
Hungary: RISPERDAL CONSTA
Iceland: RISPERDAL CONSTA
Ireland: RISPERDAL CONSTA
Italy: RISPERDAL
Lithuania: RISPOLEPT CONSTA
Latvia: RISPOLEPT CONSTA
Liechtenstein: RISPERDAL CONSTA
Luxembourg: RISPERDAL CONSTA
Malta: RISPERDAL CONSTA
Netherlands: RISPERDAL CONSTA
Norway: RISPERDAL CONSTA
Poland: RISPOLEPT CONSTA
Portugal: RISPERDAL CONSTA
Romania: RISPOLEPT CONSTA
Slovakia: RISPERDAL CONSTA
Slovenia: RISPERDAL CONSTA
Spain: RISPERDAL CONSTA
Sweden: RISPERDAL CONSTA
United Kingdom: RISPERDAL CONSTA
This leaflet was last revised in:April 2021.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
IMPORTANT INFORMATION FOR THE HEALTHCARE PROFESSIONAL
Important Information
RISPERDAL CONSTA requires detailed attention to each step of the "Instructions for Use" to help ensure successful administration.
Use of Provided Components
The container components are specifically designed for use with RISPERDAL CONSTA. RISPERDAL CONSTA should only be reconstituted with the supplied solvent.
Do notsubstitute anyof the container components.
Do notstore the suspension after reconstitution.
Administer the dose as soon as possible after reconstitution to avoid sedimentation.
Appropriate Dose
The entire contents of the vial must be administered to ensure that the appropriate dose of RISPERDAL CONSTA is administered.

Do not reuse.Medical devices require materials with specific characteristics to function properly. These characteristics have been verified for single use. Any attempt to reprocess the device for subsequent reuse may negatively affect the integrity of the device or lead to deterioration of its function.
Container Components


Step 1  | Assemble the Components  | ||
Remove the Dose Container  | Attach the Vial Adapter to the Vial  | ||
 Wait 30 Minutes Remove the dose container from the refrigerator and let it reach room temperature for at least 30 minutesbefore reconstituting. Do not heatin any other way.  | 
 Remove the Vial Cap Remove the colored cap from the vial. Clean the top of the gray stopper with an alcohol swab. Let it air dry. Do notremove the gray rubber stopper.  | 
 Prepare the Vial Adapter Hold the sterile blister as shown. Remove the paper support. Do notremove the vial adapter from the blister. Do nottouch the tip of the spike at any time. This can lead to contamination.  | 
 Attach the Vial Adapter to the Vial Place the vial on a hard surface and hold it by the base. Center the vial adapter over the gray rubber stopper. Press the vial adapter straight down until it clicks securely into place. Do notplace the vial adapter at an angle, as this may cause loss of solvent during transfer to the vial. 
  | 
Attach the Preloaded Syringe to the Vial Adapter
 Remove the Sterile Blister 
 Keep the vial upright to prevent spills. Hold the base of the vial and pull the sterile blister to remove it. Do notshake. Do nottouch the exposed luer (cone) on the vial adapter. This can lead to contamination.  | 
 Use the Correct Grip Hold by the white ring on the tip of the syringe. Do nothold the syringe by the glass during assembly. 
  | 
 Remove the Cap Holding the white ring, break the white cap. Do nottwist or cut the white cap. Do nottouch the tip of the syringe. This can lead to contamination. 
  | 
 Attach the Syringe to the Vial Adapter Hold the vial adapter by the edge to keep it in place. Hold the syringe by the white ringand then insert the tip into the luer (cone) opening of the vial adapter. Do nothold the syringe by the glass cylinder. This can cause the white ring to loosen or detach. Connect the syringe to the vial adapter with a firm clockwise rotationuntil it is secure. Do notpress too hard. Pressing too hard can cause the syringe tip to break.  | 
Step 2  | Reconstitute the Microspheres  | ||
 Inject Solvent Inject all of the solvent from the syringe into the vial. 
  | 
 Suspend the Microspheres in the Solvent Continue pressing down on the plunger with your thumb, vigorously agitateas shown, for at least 10 seconds. Check the suspension. When properly mixed, the suspension will have a uniform, dense, and milky appearance. The microspheres will be visible in the liquid. Immediately proceed with the next step to avoid sedimentation of the suspension.  | 
 Transfer the Suspension to the Syringe Invert the vial completely. Slowly pull the plunger rod down to transfer all of the vial contents to the syringe.  | 
 Remove the Vial Adapter Hold the syringe by the white ring and unscrew it from the vial adapter. Cut the vial label at the perforated area. Place the removed label on the syringe to identify it. Properly dispose of both the vial and the vial adapter (see section 5 of this leaflet).  | 
Step 3  | Attach the Needle  | |||
 Select the Appropriate Needle Select the needle according to the injection site (gluteal or deltoid).  | 
 Attach the Needle Open the blister bag at the partially detached area and use it to grasp the base of the needle, as shown. Holding the white ring of the syringe, attach the syringe to the luer (cone) of the needle with a firm clockwise rotationuntil it is secure. Do nottouch the luer (cone) opening of the needle. This can lead to contamination.  | 
 Resuspend the Microspheres Completely remove the blister bag. Just before injection, vigorously agitate the syringe again, in case any sedimentation has occurred.  | ||
Step 4  | Inject the Dose  | |||
 Remove the Transparent Protector from the Needle Move the needle safety device towards the syringe, as shown. Then, holding the white ring of the syringe, carefully remove the transparent protector from the needle. Do nottwist the transparent protector from the needle, as the luer (cone) connection may be lost.  | 
 Eliminate Air Bubbles Hold the syringe upright and gently tap to make the air bubbles rise to the top. Slowly and carefully, press the plunger to eliminate the air.  | 
 Inject Immediately inject the entire contents of the syringe intramuscularly (IM) into the gluteal or deltoid muscle of the patient. The gluteal injection should be given in the upper outer quadrant of the gluteal area. Do not administer intravenously.  | 
 Protect the Needle in the Safety Device Using one hand, place the needle safety device at a 45-degree angle on a flat, hard surface. Press down firmly and quickly until the needle is completely inside the safety device. To avoid a needlestick: Do notuse two hands. Do notdeliberately disconnect or mishandle the needle safety device. Do notattempt to straighten the needle or attach the safety device if the needle is bent or damaged.  | 
 Properly Dispose of the Needles Check that the needle safety device is completely attached. Dispose of it in a container for used needles. Also, dispose of the unused needle provided in the dose container (see section 5 of this leaflet).  | 
The average price of RISPERDAL CONSTA 50 mg POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INTRAMUSCULAR INJECTION in November, 2025 is around 138.28 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for RISPERDAL CONSTA 50 mg POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INTRAMUSCULAR INJECTION – subject to medical assessment and local rules.